Barragán-Garfias JA

Idioma: Español
Referencias bibliográficas: 34
Paginas: 52-57
Archivo PDF: 344.43 Kb.

RESUMEN

La introducción de la terapia biológica dirigida contra el factor de necrosis tumoral como tratamiento de ciertas enfermedades del tejido conectivo, como artritis reumatoide y las espondiloartropatías seronegativas en el campo de la reumatología, psoriasis en la dermatología y enfermedad inflamatoria intestinal en gastroenterología ha dado pauta para cambiar la evolución de la enfermedad y tener una alternativa para pacientes resistentes a la terapia convencional. En varios estudios ha demostrado su efectividad; sin embargo, desde la introducción de la terapia biológica con anticuerpos antifactor de necrosis tumoral (anti-FNT) se ha reportado un aumento en la incidencia de tuberculosis pulmonar y extrapulmonar, por lo que es importante realizar un adecuado protocolo de estudio previo al inicio del tratamiento con medicamentos anti-TNF para identificar a los pacientes con tuberculosis latente y disminuir el riesgo de reactivación de la enfermedad.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Adalimumab/infliximab: Tuberculosis flare: 5 case reports. Reactions Weekly 2005;5:1192.

2. Adalimumab: Disseminated miliary tuberculosis in an elderly patient: case report. Reactions Weekly 2007;5:1135.

3. Gardam M, Keystone E, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanism of action and clinical management. Lancet Infect Dis 2003;3:148-155.

4. Kobashi Y, Mouri K, Yagi S, et al. Clinical utility of the Quanti-FERON TB-2G test for elderly patients with active tuberculosis. Chest 2008;133:1196-1202.

5. Beretich G, Carter P, Havell E, et al. Roles for tumor necrosis factor and gamma interferon in resistance to enteric listeriosis. Infect Immun 1998;66:2368-2373.

6. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-1104.

7. Manadan AM, Mohan AK, Cote TR, Siegel JN, Sequeira W, Block JA. Tuberculosis and etanercept. Proceedings of American College of Rheumatology Conference; October 2002; abstr 356.

8. Papadakis KA, Targan SR. Tumor necrosis factor: biology and therapeutic implications. Gastroenterology 2000;119:1148-1157.

9. Velestini G, Lannuccelli C, Marocchi E, Pascoli L, et al. Biological and clinical effects of anti-TNF alpha treatment. Autoimmun Rev 2007;(1):35-41.

10. Klaresfog L, Van der Heijde D, Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004;363:675-681.

11. Van der Heijide D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis Rheum 2006;54:1063-1074.

12. Bandt J, Khariouzov A, Listing J, et al. Six-month results of double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing sponylitis. Arthritis Rheum 2003;48:1667-1675.

13. Davos JC, Van der Heijde D, Braun J, et al. Recombinant human TNF receptor (etanercept) for treating ankylosing spondylitis. Arthritis Rheum. 2003;48:3230-3236.

14. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis a randomized trial. Lancet 2000;356:385-390.

15. Moreland LW, Weinblant ME, Keystone EC, et al. Etanercept treatment in adults with established Rheumatoid Arthritis: 7 years of clinical experience. J Rheumatol 2006;33:854-861.

16. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-TNF alpha therapy for inflammatory arthritides. Arthritis Rheum.2003;44:2862-2869.

17. Enbrel (etanercept) prescribing information. Thousand Oaks (CA): Immunex Corporation, 2005.

18. Callegan P, Dabbous O, Keenan G, et al. A review of reports of lymphoma occurring in patients with rheumatoid arthritis in the consortium of rheumatology researchers of North America (CORRONA) database. Ann Rheum Dis. 2007;66 Suppl 1:165.

19. Saketkoo L, Espinoza L. Impact of biologic agents on infectious disease. Infect Dis Clin N Am 2006;20;931-961.

20. Van de Putte L, Rau R, Breedveld F, et al. Efficacy and safety of the fully human anti-TNF alpha monoclonal antibody adalimumab in DMAD refractory patients with rheumatoid arthritis: A 12 week, phase II study. Ann Rheum Dis 2003;62:1168-1177.

21. Weinblatt M, Keystone E, Furst D, et al. Adalimumab: a human fully anti-TNF alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA trial. Arthritis Rheum 2003;48:35-45.

22. Haibel H, Rudwaleit M, Brandt H, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two week open label trial. Arthritis Rheum 2006;4:678-681.

23. Van der Heijde D, Kiviz A, Schiff M, et al. Efficacy and safety of adalimumab in patients with ankilosing spondylitis. Arthritis Rheum 2006;54:2136-2146.

24. Bean AG, Roach DR, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-3511.

25. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. J Rheumatol 2003;30:1436-1439.

26. Wallis RS. Infectious complications of TNF antagonists. Presented at the IDSA 44th Annual Meeting. Toronto, Canada, November 2006.

27. Van der Heijde D, Klareskog L, Rodríguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis. Arthritis & Rheum 2006;54:1063-1074.

28. Roach RR, Bean AGD, Demangel C, France MP, et al. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-4627.

29. Mohan VP, Scanga CA, Yu K, et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: possible role for limiting pathology. Infect Immun 2001;69:1847-1855.

30. Flynn JL, Goldstein MM, Chan J, et al. Tumor necrosis factor is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-572.

31. Balcewicz-Sablinska MK, Keane J, Kornfeld H, Remold HG. Pathogenic Mycobacterium tuberculosis evades apoptosis of host macrophages by release of TNF-R2, resulting in inactivation of TNF-alpha. J Immunol 1998;161:2636-2641.

32. Gardam M, Keystone E, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. The Lancet Infec Dis 2003;3:148-155.

33. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-1156.